Drug intelligence / Profile preview

liposomal cisplatin + paclitaxel

Development stage: Unknown
Lead developer: Regulon
Modality: Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of liposomal cisplatin (Lipoplatin) and paclitaxel. Liposomal cisplatin is a formulation where cisplatin is encapsulated in liposomes to reduce systemic toxicity while improving tumor targeting. When combined with paclitaxel, this regimen shows significantly reduced nephrotoxicity, neurotoxicity, gastrointestinal side effects, and hematological toxicity compared to conventional cisplatin + paclitaxel combinations, while maintaining similar efficacy in terms of tumor progression and survival rates.

Other names: Lipoplatin + paclitaxel

Targets

DNATUBB (Tubulin (alpha and beta subunits))TXNRD2 (Thioredoxin reductase 2)Microtubule

Beyond the preview

Go deeper on liposomal cisplatin + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on liposomal cisplatin + paclitaxel.